Apellis PharmaceuticalsAPLS
APLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 710
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more call options, than puts
Call options by funds: $104M | Put options by funds: $33.5M
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
20% more capital invested
Capital invested by funds: $3.38B [Q3] → $4.04B (+$667M) [Q4]
5.73% more ownership
Funds ownership: 96.14% [Q3] → 101.87% (+5.73%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
2% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 61
2% less funds holding
Funds holding: 261 [Q3] → 257 (-4) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
9%
upside
Avg. target
$38
99%
upside
High target
$57
197%
upside
7 analyst ratings
3 positive
43%
4 neutral
57%
0 negative
0%
Cantor Fitzgerald Eliana Merle 20% 1-year accuracy 4 / 20 met price target | 129%upside $44 | Overweight Initiated | 29 Apr 2025 |
RBC Capital Luca Issi 20% 1-year accuracy 11 / 54 met price target | 9%upside $21 | Sector Perform Maintained | 21 Apr 2025 |
Scotiabank Greg Harrison 33% 1-year accuracy 14 / 42 met price target | 61%upside $31 | Sector Perform Maintained | 2 Apr 2025 |
JP Morgan Anupam Rama 22% 1-year accuracy 13 / 60 met price target | 181%upside $54 | Overweight Maintained | 4 Mar 2025 |
Goldman Sachs Salveen Richter 20% 1-year accuracy 4 / 20 met price target | 67%upside $32 | Neutral Maintained | 3 Mar 2025 |
Financial journalist opinion
Based on 6 articles about APLS published over the past 30 days
Neutral
GlobeNewsWire
21 hours ago
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m.
Negative
Zacks Investment Research
1 day ago
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.
Positive
Zacks Investment Research
4 weeks ago
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Positive
Benzinga
4 weeks ago
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Neutral
GlobeNewsWire
4 weeks ago
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.
Positive
Seeking Alpha
1 month ago
Apellis Pharmaceuticals: A Mixed Bag
Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand.
Positive
Benzinga
1 month ago
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst
Last week, Apellis Pharmaceuticals Inc APLS reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million, beating the consensus of $198.35 million.
Positive
Zacks Investment Research
1 month ago
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Neutral
Seeking Alpha
1 month ago
Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Cedric Francois - Co-Founder and CEO Caroline Baumal - Chief Medical Officer David Acheson - EVP, Commercial Tim Sullivan - CFO Meredith Kaya - SVP, IR and Strategic Finance Conference Call Participants Jon Miller - Evercore ISI Tazeen Ahmad - Bank of America Securities Malcolm Kuno - J.P. Morgan Salveen Richter - Goldman Sachs Yigal Nochomovitz - Citigroup Colleen Cusi - Robert W.
Charts implemented using Lightweight Charts™